natgillin/translations-raw huggingface dataset:
The difference in occurrence of pain was 9.9% (95% confidence interval 4.0-15.8%) between the Velactis treated cows compared to placebo treated animals. 
Razlika u pojavi boli bila je 9,9% (95% interval pouzdanosti; 4,0-15,8%) između krava liječenih Velactisom i životinja liječenih placebom.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Label of 5 ml vial 
OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKOVANJIMA
For cows considered likely to be free of subclinical mastitis at drying off, in which antibiotic use is not justified/permitted, Velactis can be used as a dry cow treatment. 
Velactis se može primijeniti kao terapija za zasušivanje krava za koje se smatra da u vrijeme zasušivanja nemaju subklinički mastitis, u kojih primjena antibiotika nije opravdana/dopuštena.
Use during pregnancy, lactation or lay 
Primjena tijekom graviditeta, laktacije ili nesenja Može se primjenjivati tijekom graviditeta.
Label of 25 ml vial 
Etiketa za bočicu od 25 ml
Cabergoline Bovine 0.10 µg/kg 0.25 µg/kg 
0,25 µg/kg 0,50 µg/kg 0,15 µg/kg 0,10 µg/kg masno tkivo jetra bubreg mišić mlijeko
Due to its pharmacological effect (inhibition of lactation) breastfeeding women should avoid contact with the product. 
Žene koje doje trebaju izbjegavati doticaj s proizvodom zbog njegovog farmakološkog djelovanja (inhibicije laktacije).
Label of 50 ml vial 
Etiketa za bočicu od 50 ml
NO ENTRY 
NEMA ZAPISA
PACKAGE LEAFLET FOR Velactis 1.12 mg/ml solution for injection for cattle. 
UPUTA O VMP ZA Velactis 1,12 mg/ml otopina za injekciju za goveda
NAME OF THE VETERINARY MEDICINAL PRODUCT Velactis 1.12 mg/ml solution for injection for cattle 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Velactis 1,12 mg/ml otopina za injekciju za goveda
NAME OF THE VETERINARY MEDICINAL PRODUCT Velactis 1.12 mg/ml solution for injection cabergoline 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Velactis 1,12 mg/ml otopina za injekciju kabergolin
NAME OF THE VETERINARY MEDICINAL PRODUCT Velactis 1.12 mg/ml solution for injection for cattle (dairy cows). 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Velactis 1,12 mg/ml otopina za injekciju za goveda (muzne krave). kabergolin
The full EPAR for Emend can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Emend nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Emend on 11 November 2003. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Emend na snazi u Europskoj uniji od 11. studenoga 2003.
Emend is a neurokinin 1 (NK1) receptor antagonist. 
Emend je antagonist receptora neurokinina 1 (NK1).
• pimozide (used to treat mental illness); 
• pimozid (upotrebljava se za liječenje mentalnih bolesti);
Emend 80 mg and 125 mg must not be taken with the following medicines: 
Emend 80 i 125 mg ne smije se uzimati sa sljedećim lijekovima:
After chemotherapy, one 80 mg capsule is taken each day for the next two days. 
Nakon kemoterapije jedna kapsula od 80 mg uzima se svaki dan sljedeća dva dana.
In the chemotherapy studies in adults, adding Emend to the standard combination was more effective than the standard combination alone. 
U kemoterapijskim ispitivanjima provedenima među odraslima dodavanje lijeka Emend standardnoj kombinaciji bilo je učinkovitije od same standardne kombinacije.
• cisapride (used to relieve certain stomach problems). 
• cisaprid (koristi se za ublažavanje određenih želučanih problema).
In PONV, Emend was as effective as ondansetron. 
Kod PONV-a Emend je bio učinkovit kao i ondansetron.
Other information about Emend 
Ostale informacije o lijeku Emend
What measures are being taken to ensure the safe and effective use of Emend? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Emend?
This is nausea and vomiting that a patient can experience after surgery. 
Riječ je o mučnini i povraćanju koju bolesnik može iskusiti nakon operacije.
In PONV, two studies were carried out in a total of 1,727 adult patients, most of whom were women undergoing gynaecological operations. 
U pogledu PONV-a provedena su dva ispitivanja na ukupno 1 727 odraslih bolesnika, većinom žena koje su bile podvrgnute ginekološkim operacijama.
The dose of Emend oral suspension to be given depends on the patient's bodyweight. 
Doza oralne suspenzije Emend daje se ovisno o tjelesnoj težini bolesnika.
It stops a chemical in the body (substance P) from binding to the NK1 receptors. 
Sprečava vezanje kemijske tvari u tijelu (tvar P) na receptore NK1.
• terfenadine, astemizole (commonly used to treat allergy symptoms - these medicines may be available without a prescription); 
• terfenadin, astemizol (često se primjenjuju za liječenje alergijskih simptoma - ti se lijekovi mogu izdavati i bez liječničkog recepta);
Emend was also shown to be effective in the first 24 hours after chemotherapy. 
Emend se pokazao učinkovitim i u prva 24 sata nakon kemoterapije.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Emend. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Emend.
In children between 6 months and 12 years of age, Emend oral suspension is given together with a 5HT3 antagonist. 
U djece u dobi od 6 mjeseci do 12 godina oralna suspenzija Emend daje se zajedno s antagonistom 5HT3.
This is a summary of the European public assessment report (EPAR) for Emend. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Emend.
For more information about treatment with Emend, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Emend pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku.
Emend is a medicine containing the active substance aprepitant. 
Emend je lijek koji sadrži djelatnu tvar aprepitant.
Emend 40 mg capsules are used to prevent postoperative nausea and vomiting (PONV) in adults. 
Kapsule Emenda od 40 mg upotrebljavaju se za sprečavanje postoperativne mučnine i povraćanja (PONV) u odraslih.
Why has Emend been approved? 
Zašto je Emend odobren?
A risk management plan has been developed to ensure that Emend is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Emend.
The most common side effect of Emend at all doses in adults (seen in between 1 and 10 patients in 100) is increased liver enzymes. 
Najčešće su nuspojave lijeka Emend pri svim dozama za odrasle (mogu se javiti u 1 do 10 bolesnika na 100) povišeni jetreni enzimi.
The first two studies involved a total of 1,094 adults receiving chemotherapy including cisplatin, and the third involved 866 adults with breast cancer who were receiving cyclophosphamide, with or without doxorubicin or epirubicin. 
U prva dva ispitivanja sudjelovalo je ukupno 1 094 odraslih koji su primali kemoterapiju uključujući cisplatin, a u trećemu je sudjelovalo 866 odraslih osoba koje boluju od raka dojke, a primali su ciklofosfamid, s doksorubicinom ili epirubicinom ili bez njih.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Emend, including the appropriate precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Emend nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
All three studies compared the effectiveness of Emend, taken in combination with dexamethasone and ondansetron, with that of the standard combination of dexamethasone and ondansetron. 
U sva tri ispitivanja uspoređivala se učinkovitost lijeka Emend, koji se uzima u kombinaciji s deksametazonom i ondansetronom, sa standardnom kombinacijom deksametazona i ondansetrona.
The main measure of effectiveness was the number of patients who had no nausea and vomiting in the five days after receiving chemotherapy. 
Glavna je mjera učinkovitosti bio broj bolesnika koji nisu osjećali mučninu ili nisu povraćali pet dana nakon primanja kemoterapije.
The CHMP decided that Emend's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je odlučio da koristi od lijeka Emend nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje u promet.
It is only given on the first day of the chemotherapy and is followed by treatment involving a corticosteroid and a 5HT3 antagonist. 
Daje se samo prvoga dana kemoterapije, a nakon njega slijedi liječenje koje uključuje kortikosteroid i antagonist 5HT3.
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. 
Emend je antiemetik, lijek koji sprečava mučninu (osjećaj slabosti) i povraćanje.
It must be given with other medicines that also prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a ‘5-HT3 antagonist' (such as ondansetron). 
Mora se davati s drugim lijekovima koji također sprečavaju mučninu i povraćanje, uključujući kortikosteroid (kao što je deksametazon) i „antagonist 5HT3” (kao što je ondansetron).
Emend 165 mg is given to adults only once, one hour before the start of chemotherapy. 
Emend 165 mg daje se odraslima samo jedanput, jedan sat prije početka kemoterapije.
Emend is used with other medicines to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer). 
Emend se upotrebljava s drugim lijekovima za sprečavanje mučnine i povraćanja uzrokovanih kemoterapijom (lijekovi koji se upotrebljavaju za liječenje raka).
What is the risk associated with Emend? 
Koji su rizici povezani s lijekom Emend?
By blocking the receptors, Emend can prevent nausea and vomiting, which often happens after chemotherapy or as a complication of surgery. 
Blokirajući receptore, Emend može spriječiti mučninu i povraćanje, koji se često javljaju nakon kemoterapije ili kao postoperativna komplikacija.
In chemotherapy, three main studies have been carried out for Emend 80 and 125 mg capsules. 
U pogledu kemoterapije provedena su tri glavna ispitivanja kapsula Emenda od 80 i 125 mg.
It is used with chemotherapy that is a moderate or high trigger of nausea and vomiting such as cisplatin, cyclophosphamide, doxorubicin or epirubicin. 
Upotrebljava se uz kemoterapiju koja uzrokuje umjerenu do snažnu mučninu i povraćanje, kao što su cisplatin, ciklofosfamid, doksorubicin ili epirubicin.
In PONV, the usual dose is one 40 mg capsule given to adults within the three hours before the patient is anaesthetised (‘put to sleep'). 
Kod PONV-a uobičajena je doza jedna kapsula od 40 mg koja se odraslima daje tri sata prije anesteziranja („uspavljivanja”) bolesnika.
It is available as capsules (40, 80, 125 and 165 mg) and as a powder to be made up into an oral (by mouth) suspension (125 mg). 
Dostupan je u kapsulama (40, 80, 125 i 165 mg) i u prahu za pripravljanje oralne (na usta) suspenzije (125 mg).
The effectiveness of Emend was also seen during a further five cycles of chemotherapy. 
Učinkovitost lijeka Emend zabilježena je i tijekom sljedećih pet ciklusa kemoterapije.
Emend oral suspension is given one hour before the start of chemotherapy, and for the next 2 days. 
Oralna suspenzija Emend daje se jedan sat prije početka kemoterapije te sljedeća dva dana.
The studies measured how many patients had a complete response, which was defined as no vomiting and no need for any other medication to control nausea and vomiting in the 24 hours after the operation. 
U ispitivanjima se mjerilo koliko je bolesnika imalo potpunu reakciju, koja se definirala kao izostanak povraćanja te potrebe za drugim lijekovima za kontrolu mučnine i povraćanja tijekom 24 sata nakon operacije.
What is Emend? 
Što je Emend?
Tests were performed to determine that Emend 165 mg produces the same amount of aprepitant in the body as a single dose of 150 mg Ivemend. 
Obavljeno je testiranje kako bi se utvrdilo proizvodi li Emend 165 mg jednaku količinu aprepitanta u tijelu kao jedna doza lijeka Ivemend od 150 mg.
A fourth study has been carried out with Emend (125 mg capsules or 125 mg oral solution) in 307 children from 6 months to 17 years of age, where Emend, taken with ondansetron (with or without dexamethasone), was compared with ondansetron alone (with or without dexamethasone). 
Četvrto ispitivanje lijeka Emend (kapsule od 125 mg ili otopina za oralnu primjenu od 125 mg) provedeno je na uzorku od 307 djece u dobi od 6 mjeseci do 17 godina, gdje se Emend, primijenjen uz ondansetron (s deksametazonom ili bez njega), uspoređivao s primjenom samoga ondansetrona (s deksametazonom ili bez njega).
Emend 80, 125 and 165 mg capsules are used in adults; children from 12 years of age may be given the 80- or 125-mg capsules and children between 6 months and 12 years of age are given the oral suspension. 
Kapsule lijeka Emend od 80, 125 i 165 mg upotrebljavaju se u odraslih; djeci starijoj od 12 godina mogu se dati kapsule od 80 ili 125 mg, a djeci od 6 mjeseci do 12 godina starosti daje se oralna suspenzija.
Two doses of Emend (40 and 125 mg as capsules) were compared with ondansetron given as an injection. 
Dvije doze lijeka Emend (kapsule od 40 i 125 mg) uspoređene su s ondansetronom koji se daje kao injekcija.
At a dose of 80, 125 and 165 mg, the other side effects seen in between 1 and 10 patients in 100 are headache, hiccups, constipation, dyspepsia (indigestion), loss of appetite, and fatigue (tiredness). 
Pri dozi od 80, 125 i 165 mg ostale nuspojave koje se mogu javiti u 1 do 10 bolesnika na 100 jesu sljedeće: glavobolja, štucanje, zatvor, dispepsija (žgaravica), gubitak apetita te iscrpljenost (umor).
In chemotherapy, the usual dose of Emend in adults and children from 12 years of age is one 125 mg capsule by mouth one hour before the start of chemotherapy. 
Tijekom kemoterapije uobičajena je doza lijeka Emend u odraslih i djece starije od 12 godina jedna kapsula od 125 mg oralno jedan sat prije početka kemoterapije.
In the study in children, around 51% (77 out of 152) of children given Emend with ondansetron had a complete response 25 to 120 hours after beginning chemotherapy, compared with 26% (39 out of 150) of children given ondansetron alone. 
U ispitivanju provedenome među djecom, u otprilike 51% (77 od 152) djece koja su primala Emend s ondansetronom zabilježena je potpuna reakcija 25 do 120 sati nakon početka kemoterapije, u usporedbi s 26% (39 od 150) djece koja su primala samo ondansetron.
Emend 165 mg capsules were shown to be bioequivalent to Ivemend 150 mg, which means that like Ivemend it can also be used to prevent nausea and vomiting caused by chemotherapy. 
Utvrđeno je da su kapsule lijeka Emend od 165 mg bioekvivalentne kapsulama lijeka Ivemend od 150 mg, što znači da se, baš kao i Ivemend, može upotrebljavati za sprečavanje mučnine i povraćanja uzrokovanih kemoterapijom.
Emend makes chemotherapy more tolerable for the patient. 
Emend bolesniku olakšava podnošenje kemoterapije.
What is Emend used for? 
Za što se Emend koristi?
Looking at the results of the two cisplatin studies taken together, 68% of the patients taking Emend had no nausea or vomiting over five days (352 out of 520), compared with 48% of the patients who did not take it (250 out of 523). 
Promatrajući rezultate dvaju istodobno provedenih ispitivanja cisplatina, u 68% bolesnika koji su primali Emend nisu zabilježeni mučnina i povraćanje u razdoblju od pet dana (352 od 520), u usporedbi s 48% bolesnika koji ga nisu primali (250 od 523).
In children, the most common side effects are hiccups and flushing. 
U djece su najčešće nuspojave štucanje i crvenilo uz osjećaj vrućine.
In the study of chemotherapy that is a moderate trigger of nausea and vomiting, 51% of the patients taking Emend had no nausea or vomiting (220 out of 433), compared with 43% of the patients who did not take it (180 out of 424). 
U ispitivanju kemoterapije koja izaziva umjerenu mučninu i povraćanje, u 51% bolesnika koji su primali Emend nisu zabilježeni mučnina i povraćanje (220 od 433), u usporedbi s 43% bolesnika koji ga nisu primali (180 od 424).
Looking at the results of both studies together, 55% of the patients (298 out of 541) taking Emend capsules at a dose of 40 mg had a complete response, compared with 49% of the patients who received ondansetron (258 out of 526). 
Promatrajući rezultate obaju ispitivanja zajedno, u 55% bolesnika (298 od 541) koji su uzimali kapsule lijeka Emend u dozi od 40 mg zabilježena je potpuna reakcija, u usporedbi s 49% bolesnika koji su primali ondansetron (258 od
The main measure of effectiveness was based on how many patients had a ‘complete response', which was defined as no vomiting, retching or dry heaves and no need for any other medication to control nausea and vomiting 25 to 120 hours after the start of chemotherapy (delayed phase).The study also looked at how many patients achieved a complete response in the first 24 hours after chemotherapy (acute phase). 
Glavna mjera učinkovitosti temeljena je na broju bolesnika kod kojih je zabilježena „potpuna reakcija”, koja se definira kao izostanak povraćanja, neuspješnog pokušaja povraćanja ili podražaja na povraćanje te izostanak potrebe za drugim lijekovima za kontrolu mučnine i povraćanja od 25 do 120 sati nakon početka kemoterapije (zakašnjela faza).
How is Emend used? 
Kako se Emend koristi?
How does Emend work? 
Kako djeluje Emend?
What benefit has Emend shown during the studies? 
Koje su koristi lijeka Emend utvrđene u ispitivanjima?
For the full list of restrictions with Emend, see the package leaflet. 
Potpuni popis ograničenja pri primjeni lijeka Emend potražite u uputi o lijeku.
For the full list of all side effects reported with Emend, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Emend potražite u uputi o lijeku.
Emend 165 mg capsules were compared with the authorised intravenous medicine Ivemend 150 mg. Ivemend contains a substance called fosaprepitant which is converted in the body into aprepitant. 
Kapsule lijeka Emend od 165 mg uspoređene su s odobrenim intravenoznim lijekom Ivemend 150 mg.
Blister (OPA/alu/PVC) 84 capsules 
Blister (OPA/alu/PVC) 84 kapsule
EU/1/17/1232/001 Miglustat Gen.Orph 
EU/1/17/1232/001 Miglustat Gen.Orph 100 mg Kapsula, tvrda
Drink it straight away. 
Popijte odmah.
Tell your doctor if you are taking, have recently taken or might take any other medicines 
Obavijestite svog liječnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
It will dissolve directly in your mouth, so that it can be easily swallowed. 
Rastopit će se izravno u vašim ustima, pa ćete je moći lako progutati.
Generally, delayed type reactions such as contact dermatitis may occur, but rarely immediate reactions with bronchospasm may occur. 
Općenito se mogu javiti odgođene reakcije kao što je kontaktni dermatitis, ali se rijetko javljaju neposredne reakcije s bronhospazmom.
These preservatives are known to cause urticaria. 
Poznato je da ovi konzervansi uzrokuju urtikariju.
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients. 
16 Povišene razine prolaktina u plazmi prijavljene su u 47,4% adolescentnih bolesnika.
ZYPREXA VELOTAB belongs to a group of medicines called antipsychotics and is used to treat the following conditions: 
ZYPREXA VELOTAB pripada skupini lijekova koji se zovu antipsihotici i koristi se za liječenje sljedećih stanja:
Your doctor will tell you how many ZYPREXA VELOTAB tablets to take and how long you should continue to take them. 
Liječnik će Vam reći koliko ZYPREXA VELOTAB tableta trebate uzeti i koliko ćete ih dugo uzimati.
In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents. 
U kliničkim ispitivanjima prosječna izloženost olanzapinu bila je približno 27% viša u adolescenata.
May be harmful for people with phenylketonuria. 
Može biti štetan u osoba s fenilketonurijom.
The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female nonsmokers and 77 % in male smokers. 
Srednja vrijednost porasta Cmax olanzapina nakon primjene fluvoksamina iznosila je 54% u žena nepušača i 77% u muškaraca pušača.
Keep this medicine out of sight and reach of children. 
Lijek čuvajte izvan pogleda i dohvata djece.
You can also place the tablet in a full glass or cup of water, orange juice, apple juice, milk or coffee, and stir. 
Tabletu također možete staviti u punu čašu ili šalicu vode, soka od naranče, soka od jabuke, mlijeka ili kave te promiješati.
This may occur immediately or some time after you take ZYPREXA VELOTAB. 
To se može dogoditi odmah ili neko vrijeme nakon uzimanja lijeka ZYPREXA VELOTAB.
Since the orodispersible tablet is fragile, it should be taken immediately on opening the blister. 
Budući da je raspadljiva tableta za usta krhka, treba je uzeti odmah nakon otvaranja blistera.
Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration. 
Alternativno se može rastopiti u čaši punoj vode ili nekom drugom prikladnom napitku (soku od naranče, soku od jabuke, mlijeku ili kavi) netom prije primjene.
However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n=467) as in male patients (n=869). 
Međutim, olanzapin (5-20 mg) je u bolesnica (n=467) pokazao profil sigurnosti usporediv s onim u bolesnika (n=869).
Do not handle the tablets with wet hands as the tablets may break up. 
Ne uzimajte tablete mokrim rukama jer se mogu prelomiti.
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available). 
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Hold the blister strip at the edges and separate one blister cell from the rest of the strip by gently tearing along the perforations around it. 
Primite blister za rubove i odvojite jedno polje blistera od ostatka trake, pažljivo trgajući duž perforacija koje ga okružuju.
Orodispersible tablet is the technical name for a tablet which dissolves directly in your mouth, so that it can be easily swallowed. 
Raspadljiva tableta za usta je tehnički naziv za tabletu koja se rastopi izravno u ustima pa se može lako progutati.
In 44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events. 
44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.
ZYPREXA VELOTAB is available in packs containing 28, 35, 56, 70 or 98 tablets. 
ZYPREXA VELOTAB dostupan je u pakiranjima s 28, 35, 56, 70 ili 98 tableta.
With some drinks, the mixture may change colour and possibly become cloudy. 
Ako se lijek uzima s pićem, mješavina može promijeniti boju i postati mutna.
ZYPREXA VELOTAB with alcohol 
ZYPREXA VELOTAB s alkoholom
You should not be given this medicine when breast-feeding, as small amounts of ZYPREXA VELOTAB can pass into breast milk. 
Ne biste smjeli uzimati ovaj lijek dok dojite, jer se male količine lijeka ZYPREXA VELOTAB mogu izlučiti u majčino mlijeko.
In patients with Parkinson's disease ZYPREXA VELOTAB may worsen the symptoms. 
U bolesnika koji boluju od Parkinsonove bolesti, ZYPREXA VELOTAB može pogoršati simptome.
(including pulmonary embolism and deep vein thrombosis) (see section 4.4) 
(uključujući plućnu emboliju i duboku vensku trombozu) (vidjeti dio 4.4)